33 min listen
Episode 230: FGFR Inhibition in NMIBC With Sia Daneshmand
FromThe Uromigos
ratings:
Length:
26 minutes
Released:
Mar 28, 2023
Format:
Podcast episode
Description
Sia Daneshmand, MD, joins the show to review 2 studies on
the use of erdafitinib for the treatment of non-muscle invasive bladder cancer,
including the THOR-2 trial investigating erdafitinib versus intravesical
chemotherapy in patients who received BCG therapy and recurred with high-risk
NMIBC. Dr. Daneshmand is the director of urologic oncology at the Keck School
of Medicine, University of Southern California, Los Angeles.
the use of erdafitinib for the treatment of non-muscle invasive bladder cancer,
including the THOR-2 trial investigating erdafitinib versus intravesical
chemotherapy in patients who received BCG therapy and recurred with high-risk
NMIBC. Dr. Daneshmand is the director of urologic oncology at the Keck School
of Medicine, University of Southern California, Los Angeles.
Released:
Mar 28, 2023
Format:
Podcast episode
Titles in the series (100)
Episode 3: Pembrolizumab in Non-Muscle Invasive Bladder Cancer by The Uromigos